-
2023-510336-36-00
5
2023-05-05
Paroxysmal nocturnal hemoglobinuria (PNH)
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-504152-97-00
5
2021-11-26
Generalized Myasthenia Gravis
-
2023-509321-50-00
5
2021-04-15
HER2-POSITIVE EARLY BREAST CANCER
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-515973-82-00
4
2025-06-23
ACPA-Positive Rheumatoid Arthritis
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2023-507306-13-00
4
2025-04-13
HER2-positive unresectable locally recurrent or metastatic breast canc
-
2024-516213-20-00
5
2025-03-25
Psoriatic arthritis
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-514786-19-01
6
2025-01-27
PROSTATE CANCER
-
2024-513952-13-00
5
2025-01-02
HR+ / HER2- advanced breast cancer
-
2024-515070-28-00
5
2024-12-23
HIV Infections
-
2024-511738-11-00
5
2024-12-18
Psoriatic arthritis
-
2023-508077-85-00
5
2024-11-19
Polymyalgia Rheumatica
-
2023-508096-36-00
5
2024-10-30
atopic dermatitis
-
2023-505739-12-01
5
2024-09-30
Chronic Inducible Urticaria (CINDU)
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State
-
2023-508235-31-00
5
2024-06-17
Atopic Dermatitis
-
2023-506702-39-00
4
2024-06-05
HER2-low breast cancer presenting with newly diagnosed or progressing